Which Parkinson's drug is associated with persistent cough and shortness of breath?

Cabergoline is associated with pulmonary complications, including persistent cough and shortness of breath. While primarily used in the treatment of Parkinson's disease and as a prolactin inhibitor, cabergoline has been linked to conditions such as pleural effusion and pulmonary fibrosis, which can manifest as respiratory symptoms. Recognizing these side effects is crucial for healthcare providers managing medications for patients with Parkinson's disease.

The other options do not have established associations with respiratory symptoms to the same extent. Ropinirole, pramipexole, and clozapine primarily target different pathways in the treatment of Parkinson’s or other related disorders, and their side effect profiles do not prominently include respiratory complications like those associated with cabergoline.